Abstract:1042 Objectives: Receptor interacting protein 1 (RIP1) kinase is a crucial upstream regulator of necroptosis, and the association of RIP1 kinase with a variety of pathologies, such as ischemic injury, inflammatory diseases, and neurodegenerative diseases(PD, MS and ALS), has been investigated. Inhibitors of RIP1 kinase have the potential to provide new therapeutic opportunities to neurodegenerative diseases with significant unmet medical needs. A new 7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine derivative was reported as a novel receptor interacting protein 1 (RIP1) kinase inhibitors. This compound significantly suppressed necroptotic cell death both in mouse and human cells. To investigate the RIP1 kinase regulate functions for the brain disorders, we radiosynthesized [11C]TZ7774 and performed initial in vivo in rodent to determine if [11C]TZ7774 could be a suitable PET radiotracer for imaging RIP1 kinase in the brain. Methods: The radiosynthesis of [11C]TZ7774 was accomplished by N-[11C]methylation of its amide precursor TZ7799 with [11C]CH3I under basic condition (NaOH) in DMF, heated at ~80 oC for 5 min. The radiolabeled product was purified on semi-preparative reversed phase HPLC column combined with solid phase extraction (SPE). The biodistribution study of [11C]TZ7774 was performed using male Sprague Dawley (SD) rats. Animals were euthanized at 5, 30, 60 min post i.v. injection of [11C]TZ7774. Tissues of interests were collected, weighed, and counted on an automated Beckman Gamma counter. The uptake of radioactivity was calculated as percentage injected dose per gram (%I.D./g). Results: The radiosynthesis of [11C]TZ7774 was successfully achieved with good radiochemical yield (30-40%), high chemical and radiochemical purity (> 99%), and high specific activity (> 700 Ci/mmol, decay corrected to EOB). The biodistribution study indicated that the initial brain uptake was high with %ID/gram values of 0.53 at 5 min and then washed out quickly with %ID/gram values of 0.14 at 30 min, and 0.07 at 60 min. Conclusions: Our preliminary biodistribution results suggested that [11C]TZ7774 has good brain uptake. Together, [11C]TZ7774 has great potential to be a PET tracer for imaging RIPK1 in vivo. Further in vitro autoradiography studies and microPET studies of [11C]TZ7774 in animal model of diseases to assess the RIP1 expression response to the progression of disease are ongoing. Research support: NIH/NS075527, NS103988. References: ADDIN EN.REFLIST J. Med. Chem., 2018, 61, 2384-2409; Cell Rep., 2015, 10, 1836-1849; Neural Regener. Res. 2015, 10,1120-1124; Science, 2016, 353, 603-608.

A Highly Potent, Orally Bioavailable Pyrazole-Derived Cannabinoid CB2 Receptor- Selective Full Agonist for In Vivo Studies

A highly potent, orally bioavailable pyrazole-derived cannabinoid CB2 receptor-selective full agonist for studies

Design, Synthesis, And Sar Studies Of Heteroarylpyrimidines And Heteroaryltriazines As Cb2r Ligands

RG7774 (Vicasinabin), an orally bioavailable cannabinoid receptor 2 (CB2R) agonist, decreases retinal vascular permeability, leukocyte adhesion, and ocular inflammation in animal models

Development and evaluation of novel PET tracers for imaging cannabinoid receptor type 2 in brain

Highly Selective Drug-Derived Fluorescent Probes for the Cannabinoid Receptor Type 1 (CB1R)

Novel Functionalized Cannabinoid Receptor Probes: Development of Exceptionally Potent Agonists

Synthesis and pharmacological characterization of UVI3502, a novel cannabinoid receptor 1 (CB1) antagonist/inverse agonist

The progress of small molecules against cannabinoid 2 receptor (CB2R)

A Novel Near-Infrared Fluorescence Imaging Probe That Preferentially Binds to Cannabinoid Receptors CB2R over CB1R.

Identification of novel mouse and rat CB1R isoforms and in silico modeling of human CB1R for peripheral cannabinoid therapeutics

Drug Derived Fluorescent Probes for the Specific Visualization of Cannabinoid Type 2 Receptor - A Toolbox Approach

Discovery of a pyrano[2,3-b]pyridine derivative YX-2102 as a cannabinoid receptor 2 agonist for alleviating lung fibrosis

High-throughput screening and in vitro evaluation of CSB-0914; a novel small molecule NF-κB inhibitor attenuating inflammatory responses through NF-κB, Nrf2 and HO-1 cross-talk

Functionalized 6-(Piperidin-1-yl)-8,9-Diphenyl Purines as Peripherally Restricted Inverse Agonists of the CB1 Receptor

Anti-Proliferative Properties and Proapoptotic Function of New CB2 Selective Cannabinoid Receptor Agonist in Jurkat Leukemia Cells

Nir760-Xlp6, A Novel Near-Infrared Fluorescence Imaging Probe That Preferentially Binds to Cannabinoid Receptors Cb2r over Cb1r

Synthesis Andin Vivocharacterization of a Promising 11-Carbon Labeled Receptor Interacting Protein 1 (RIP1) Kinase Radioligand

Identification of a Novel Neuropeptide S Receptor Antagonist Scaffold Based on the SHA-68 Core

Rational design of cannabinoid type-1 receptor allosteric modulators: Org27569 and PSNCBAM-1 hybrids

Characterization of [3H]AZ12464237 as a high affinity, non-nucleotide antagonist radioligand for the P2Y12 receptor